Prediction of Functional Recovery in Patients With Intracerebral Hemorrhage (NCT07728734) | Clinical Trial Compass
By InvitationNot Applicable
Prediction of Functional Recovery in Patients With Intracerebral Hemorrhage
Spain1,688 participantsStarted 2026-07-01
Plain-language summary
Currently, we lack sufficiently reliable tools to accurately predict, in the first few hours, the vital prognosis, functional status, and quality of life of patients with intracerebral hemorrhage (ICH). With new neurosurgical techniques and improvements in neurocritical care, it is essential to adapt therapeutic decisions to the wishes of patients and their families. Doing so based on a reliable functional prognosis will reduce arbitrariness in treatments and help avoid situations of unwanted dependency and high social and healthcare costs.
This project aims to validate, in several hospitals in Spain and in real-world clinical practice, a new, easy-to-implement predictive scale that estimates the probability of functional recovery in patients with ICH in the short and long term. It will also analyze new prognostic blood biomarkers that could enhance the scale's accuracy.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Patients ≥ 18 years diagnosed with spontaneous intracranial hemorrhage (ICH) by CT scan and treated maximally within the first 24 hours.
. Prior functional independence defined as modified Rankin scale (mRS) ≤ 3.
. Time from symptom onset or last known seen well ≤ 24 hours.
. Signed informed consent by the patient or their representative.
Exclusion criteria
. Age \< 18 years
. Intracranial hemorrhage secondary to trauma, ischemic stroke, or fibrinolytic or endovascular treatment.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
GOOD OUTCOME: A MODIFIED RANKIN SCORE (mRS) OF 0-3
. Spontaneous ICH with limitation of therapeutic effort (LTE) within the first 24 hours. LTE is defined as the withholding or withdrawal of potentially life-sustaining treatment and/or the initiation of comfort care measures with the expectation that the patient may die as a result. Potentially life-sustaining treatments include: orotracheal intubation and mechanical ventilation, cardiopulmonary resuscitation, and neurosurgical treatments (intracranial pressure monitoring, external ventricular drainage, hematoma evacuation, decompressive craniectomy). LTE is not considered to apply if only a do-not-resuscitate (DNR) order was established, without limitation of any other treatment.
. Prior functional dependence, defined as mRS \> 3
. Time from symptom onset or last known seen well \>24 hours